ACCESS Newswire

Northway Biotech

Share
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
tiakis Biotech AG and Northway Biotech collaboration
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.

The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.

Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."

André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."

By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.

About Tiprelestat

tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.

About tiakis Biotech AG

tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).

About Northway Biotech

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.

Contact Information

Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com

SOURCE: Northway Biotech

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

TruMerit Adds Two More Global Credentials for Rehabilitation Care Workers16.9.2025 20:00:00 CEST | Press release

PHILADELPHIA, PA / ACCESS Newswire / September 16, 2025 / TruMerit, a global leader in healthcare workforce development, today launched two new global credentials for healthcare workers specializing in rehabilitation, habilitation, and restorative care. The Certified Global Health Worker-Rehabilitation (CGHW-R) and the Certified Global Health Worker-Rehabilitation Advanced (CGHW-RA) have been developed specifically for eligible health workers worldwide who wish to have their applied experience and competencies in rehab care recognized and verified by passing a certification examination. These credentials, along with the Certified Global Nurse-Rehabilitation (CGN-R) that TruMerit established last year, are intended to advance and improve services for the more than two billion people worldwide who need this care. The CGHW-RA credential was developed for those with a degree or diploma in a rehabilitation field. These include clinicians, educators, and instructors with physiotherapy, occup

Second Blue Magic Netherlands Event Set for November 1816.9.2025 18:30:00 CEST | Press release

Registration Site Is Open and Dutch Innovators Are Encouraged to Attend and Apply to Present Capabilities SAN DIEGO, CALIFORNIA / ACCESS Newswire / September 16, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI), in collaboration with the Dutch Ministry of Defence and the Dutch Ministry of Economic Affairs, will host its second Blue Magic Netherlands (BMNL) event on November 18, 2025. BMNL 2025 follows the successful first event in 2024 and will take place at the MELT at Avular building, a world-class venue for technology interchange near Brainport Eindhoven, the center of the Dutch high-technology manufacturing industry. The registration site can be accessed at www.ga-asi.com/blue-magic-netherlands-2025. "The first BMNL event was a huge success for Dutch industry," said Brad Lunn, managing director for GA-ASI. "We've built strong investment opportunities with Dutch companies - including Arceon, Emergent Swarm Solutions, and Saluqi Motors - and now we're looking to build on th

U.S. Polo Assn. Celebrates Sport and Style as Official Apparel Sponsor of the 2025 Engel & Völkers Berlin Maifeld Polo Cup16.9.2025 13:00:00 CEST | Press release

Sports Brand Supports Germany's High-Goal Polo Event for Sixth Consecutive Year BERLIN, GERMANY AND WEST PALM BEACH, FL / ACCESS Newswire / September 16, 2025 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly partnered as the Official Jersey and Apparel Sponsor of the Engel & Völkers Berlin Maifeld Polo Cup, also known as the German High-Goal Championship 2025, held August 22-31, 2025, in Berlin. This prestigious tournament is the pinnacle of the polo season in Germany and is one of the most celebrated events in European polo.Engel & Völkers Berlin Maifeld Polo Cup Winners Photo Credit: Guadalupe Aizaga The finals weekend for the Engel & Völkers Berlin Maifeld Polo Cup took place at the iconic Maifeld Stadium, the same historic venue where the sport of polo was last played in the 1936 Olympic Games. Qualifying matches were held August 21-28 at the Prussian Polo and Country Club, leading to a thrilling finale that showcased the very best

Case IQ Introduces Clairia: AI Assistant for Compliance, Workplace Investigations and Case Management16.9.2025 11:00:00 CEST | Press release

Transforming how ethics, compliance, and HR teams across Europe resolve cases with speed, intelligence and confidence. LONDON, GB / ACCESS Newswire / September 16, 2025 / Case IQ has announced the launch of Clairia, an AI assistant designed to simplify case management and provide clarity at every step. Clairia empowers European organizations, HR teams, and compliance officers to manage cases with efficiency, speed and confidence from the initial complaint or report to case resolution. Clairia is built into Case IQ's case management solution and is designed for ethics, compliance, HR, and investigations teams who require accuracy, consistency, and accountability. It delivers clear and context-aware suggestions on how to proceed that draw on uploaded documents such as internal codes of conduct and applicable regulatory frameworks like the EU Whistleblower Directive, and most recently in the UK, the new corporate criminal offence of "Failure to Prevent Fraud" under the Economic Crime and

Clean Air Metals Announces Appointment of John Mason as Director15.9.2025 13:00:00 CEST | Press release

THUNDER BAY, ON / ACCESS Newswire / September 15, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB: CLRMF) is pleased to announce the appointment of John Mason, D.Sc., P.Geo., as Director of the Company effective immediately. John Mason is a professional geoscientist with 49 years of experience in mineral exploration and mining in Northern Ontario. Mr. Mason's work experience includes management positions with the Ontario Ministry of Northern Development and Mines (NDMNRF) and Thunder Bay Community Economic Development Commission, before starting John Mason and Associates. John Mason has worked with all mines and major exploration projects in Northwestern Ontario, specific to supply and service, workforce, energy, and transportation access needs. John has worked with many of the indigenous communities, MNO and municipalities to maximize economic development opportunities related to exploration and mining and balance environmental/ESG require

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye